|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics. CA Cancer
J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Desantis C and Jemal A:
Colorectal cancer statistics, 2014. CA Cancer J Clin. 64:104–117.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cui S, Gao Y, Zhang K, Chen J, Wang R and
Chen L: The emerging role of inhibitor of growth 4 as a tumor
suppressor in multiple human cancers. Cell Physiol Biochem.
36:409–422. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Guérillon C, Bigot N and Pedeux R: The ING
tumor suppressor genes: Status in human tumors. Cancer Lett.
345:1–16. 2014. View Article : Google Scholar
|
|
5
|
Kim S, Chin K, Gray JW and Bishop JM: A
screen for genes that suppress loss of contact inhibition:
Identification of ING4 as a candidate tumor suppressor gene in
human cancer. Proc Natl Acad Sci USA. 101:16251–16256. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shiseki M, Nagashima M, Pedeux RM,
Kitahama-Shiseki M, Miura K, Okamura S, Onogi H, Higashimoto Y,
Appella E, Yokota J, et al: p29ING4 and p28ING5 bind to p53 and
p300, and enhance p53 activity. Cancer Res. 63:2373–2378.
2003.PubMed/NCBI
|
|
7
|
Xie Y, Zhang H, Sheng W, Xiang J, Ye Z and
Yang J: Adenovirus-mediated ING4 expression suppresses lung
carcinoma cell growth via induction of cell cycle alteration and
apoptosis and inhibition of tumor invasion and angiogenesis. Cancer
Lett. 271:105–116. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gong A, Ye S, Xiong E, Guo W, Zhang Y,
Peng W, Shao G, Jin J, Zhang Z, Yang J, et al: Autophagy
contributes to ING4-induced glioma cell death. Exp Cell Res.
319:1714–1723. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xie Y, Sheng W, Miao J, Xiang J and Yang
J: Enhanced antitumor activity by combining an adenovirus harboring
ING4 with cisplatin for hepatocarcinoma cells. Cancer Gene Ther.
18:176–188. 2011. View Article : Google Scholar :
|
|
10
|
Zhang X, Xu LS, Wang ZQ, Wang KS, Li N,
Cheng ZH, Huang SZ, Wei DZ and Han ZG: ING4 induces G2/M cell cycle
arrest and enhances the chemosensitivity to DNA-damage agents in
HepG2 cells. FEBS Lett. 570:7–12. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang R, Huang J, Feng B, De W and Chen L:
Identification of ING4 (inhibitor of growth 4) as a modulator of
docetaxel sensitivity in human lung adenocarcinoma. Mol Med.
18:874–886. 2012.PubMed/NCBI
|
|
12
|
Zhao Y, Su C, Zhai H, Tian Y, Sheng W,
Miao J and Yang J: Synergistic antitumor effect of
adenovirus-mediated hING4 gene therapy and 125I
radiation therapy on pancreatic cancer. Cancer Lett. 316:211–218.
2012. View Article : Google Scholar
|
|
13
|
Ling C, Xie Y, Zhao D, Zhu Y, Xiang J and
Yang J: Enhanced radiosensitivity of non-small-cell lung cancer
(NSCLC) by adenovirus-mediated ING4 gene therapy. Cancer Gene Ther.
19:697–706. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhu Y, Lv H, Xie Y, Sheng W, Xiang J and
Yang J: Enhanced tumor suppression by an ING4/IL-24 bicistronic
adenovirus-mediated gene cotransfer in human non-small cell lung
cancer cells. Cancer Gene Ther. 18:627–636. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xie Y, Lv H, Sheng W, Miao J, Xiang J and
Yang J: Synergistic tumor suppression by adenovirus-mediated
inhibitor of growth 4 and interleukin-24 gene cotransfer in
hepatocarcinoma cells. Cancer Biother Radiopharm. 26:681–695. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shen JC, Unoki M, Ythier D, Duperray A,
Varticovski L, Kumamoto K, Pedeux R and Harris CC: Inhibitor of
growth 4 suppresses cell spreading and cell migration by
interacting with a novel binding partner, liprin alpha1. Cancer
Res. 67:2552–2558. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li J, Martinka M and Li G: Role of ING4 in
human melanoma cell migration, invasion and patient survival.
Carcinogenesis. 29:1373–1379. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Garkavtsev I, Kozin SV, Chernova O, Xu L,
Winkler F, Brown E, Barnett GH and Jain RK: The candidate tumour
suppressor protein ING4 regulates brain tumour growth and
angiogenesis. Nature. 428:328–332. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ozer A, Wu LC and Bruick RK: The candidate
tumor suppressor ING4 represses activation of the hypoxia inducible
factor (HIF). Proc Natl Acad Sci USA. 102:7481–7486. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Colla S, Tagliaferri S, Morandi F, Lunghi
P, Donofrio G, Martorana D, Mancini C, Lazzaretti M, Mazzera L,
Ravanetti L, et al: The new tumor-suppressor gene inhibitor of
growth family member 4 (ING4) regulates the production of
proangiogenic molecules by myeloma cells and suppresses
hypoxia-inducible factor-1 alpha (HIF-1alpha) activity: Involvement
in myeloma-induced angiogenesis. Blood. 110:4464–4475. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lu M, Pan C, Zhang L, Ding C, Chen F, Wang
Q, Wang K and Zhang X: ING4 inhibits the translation of
proto-oncogene MYC by interacting with AUF1. FEBS Lett.
587:1597–1604. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
You Q, Wang XS, Fu SB and Jin XM:
Downregulated expression of inhibitor of growth 4 (ING4) in
advanced colorectal cancers: A non-randomized experimental study.
Pathol Oncol Res. 17:473–477. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lou C, Jiang S, Guo X and Dong XS: ING4 is
negatively correlated with microvessel density in colon cancer.
Tumour Biol. 33:2357–2364. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Schmittgen TD and Livak KJ: Analyzing
real-time PCR data by the comparative CT method. Nat
Protoc. 3:1101–1108. 2008. View Article : Google Scholar
|
|
25
|
Tiscornia G, Singer O and Verma IM:
Production and purification of lentiviral vectors. Nat Protoc.
1:241–245. 2006. View Article : Google Scholar
|
|
26
|
Weidner N: Current pathologic methods for
measuring intratumoral microvessel density within breast carcinoma
and other solid tumors. Breast Cancer Res Treat. 36:169–180. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Massagué J: G1 cell cycle control and
cancer. Nature. 432:298–306. 2004. View Article : Google Scholar
|
|
28
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Welti J, Loges S, Dimmeler S and Carmeliet
P: Recent molecular discoveries in angiogenesis and antiangiogenic
therapies in cancer. J Clin Invest. 123:3190–3200. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shang B, Cao Z and Zhou Q: Progress in
tumor vascular normalization for anticancer therapy: Challenges and
perspectives. Front Med. 6:67–78. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ferrara N: VEGF and the quest for tumour
angiogenesis factors. Nat Rev Cancer. 2:795–803. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chaffer CL and Weinberg RA: A perspective
on cancer cell metastasis. Science. 331:1559–1564. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lamouille S, Xu J and Derynck R: Molecular
mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell
Biol. 15:178–196. 2014. View Article : Google Scholar : PubMed/NCBI
|
